Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more
Market Cap & Net Worth: Lasa Supergenerics Limited (LASA)
Lasa Supergenerics Limited (NSE:LASA) has a market capitalization of $4.22 Million (₹365.24 Million) as of March 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #34906 globally and #1950 in its home market, demonstrating a -7.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lasa Supergenerics Limited's stock price ₹7.29 by its total outstanding shares 50101239 (50.10 Million).
Lasa Supergenerics Limited Market Cap History: 2017 to 2026
Lasa Supergenerics Limited's market capitalization history from 2017 to 2026. Data shows change from $103.65 Million to $4.22 Million (-29.72% CAGR).
Lasa Supergenerics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lasa Supergenerics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Lasa Supergenerics Limited's market cap is 0.00 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $103.65 Million | $1.99 Billion | $23.62 Million | 0.05x | 4.39x |
| 2018 | $17.27 Million | $2.44 Billion | $123.40 Million | 0.01x | 0.14x |
| 2019 | $10.25 Million | $1.70 Billion | -$120.31 Million | 0.01x | N/A |
| 2020 | $48.46 Million | $1.67 Billion | $36.28 Million | 0.03x | 1.34x |
| 2021 | $39.43 Million | $2.02 Billion | $227.78 Million | 0.02x | 0.17x |
| 2022 | $19.47 Million | $1.37 Billion | -$53.31 Million | 0.01x | N/A |
| 2023 | $17.30 Million | $1.30 Billion | -$386.21 Million | 0.01x | N/A |
| 2024 | $14.72 Million | $1.04 Billion | -$217.31 Million | 0.01x | N/A |
| 2025 | $5.46 Million | $1.42 Billion | -$147.57 Million | 0.00x | N/A |
Competitor Companies of LASA by Market Capitalization
Companies near Lasa Supergenerics Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Lasa Supergenerics Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Lasa Supergenerics Limited Historical Marketcap From 2017 to 2026
Between 2017 and today, Lasa Supergenerics Limited's market cap moved from $103.65 Million to $ 4.22 Million, with a yearly change of -29.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹4.22 Million | -22.78% |
| 2025 | ₹5.46 Million | -62.89% |
| 2024 | ₹14.72 Million | -14.92% |
| 2023 | ₹17.30 Million | -11.14% |
| 2022 | ₹19.47 Million | -50.63% |
| 2021 | ₹39.43 Million | -18.63% |
| 2020 | ₹48.46 Million | +372.63% |
| 2019 | ₹10.25 Million | -40.63% |
| 2018 | ₹17.27 Million | -83.34% |
| 2017 | ₹103.65 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Lasa Supergenerics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.22 Million USD |
| MoneyControl | $4.22 Million USD |
| MarketWatch | $4.22 Million USD |
| marketcap.company | $4.22 Million USD |
| Reuters | $4.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.